Marker Therapeutics to Present at Three Upcoming September Investor Conferences
Marker Therapeutics, Inc. (NASDAQ: MRKR), a leader in clinical-stage immuno-oncology, will present at three virtual investor conferences this September.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Marker Therapeutics, Inc. (NASDAQ: MRKR), a leader in clinical-stage immuno-oncology, will present at three virtual investor conferences this September. The conferences include the H.C. Wainwright Annual Global Investment Conference on September 13, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, and the Cantor Fitzgerald Global Healthcare Conference on September 27. Presentations will feature key executives, including CFO Anthony H. Kim and CMO Mythili Koneru. Webcasts will be available on the company’s website.
Details
News Market Reaction – MRKR
The recorded move for MRKR in the trading session of this news was -0.51%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, Sept. 7, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company will present at three upcoming virtual investor conferences in September.
Conference Details
H.C. Wainwright Annual Global Investment Conference
Company Presenter: Anthony H. Kim, Chief Financial Officer
Date: Monday, September 13, 2021
Time: On-demand beginning at 7:00 a.m. ET
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Company Presenter: Mythili Koneru, M.D., Ph.D., Chief Medical Officer
Date: Wednesday, September 22, 2021
Time: 9:05 a.m. ET
Cantor Fitzgerald Global Healthcare Conference
Fireside Chat
Date: Monday, September 27, 2021
Time: 10:40 a.m. ET
Live webcasts of the presentations will be accessible from the Investors section of the company's website at markertherapeutics.com and will be available for replay following the event.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.
View original content to download multimedia:https://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-three-upcoming-september-investor-conferences-301370677.html
SOURCE Marker Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.